148 results on '"Simon, Jakub K."'
Search Results
2. Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates
3. Vaccine Development in the Midst of Ebolavirus Disease Outbreaks
4. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV: a randomized phase 3 study
5. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
6. Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
7. Accelerating Vaccine Development During the 2013–2016 West African Ebola Virus Disease Outbreak
8. Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection
9. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18–45
10. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus–Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults
11. Identification of immune correlates of protection in Shigella infection by application of machine learning
12. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 E1 Tor
13. Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials
14. Association Between State Hepatitis A Vaccination Requirements and Hepatitis A Vaccination Rates
15. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE)
16. Applications of nanotechnology for immunology
17. Effects of Gamma Irradiation of Human Serum Samples from rVSVΔG-ZEBOV-GP (V920) Ebola Virus Vaccine Recipients on Plaque-Reduction Neutralization Assays
18. Using the power law model to predict the long-term persistence and duration of detectable hepatitis A antibody after receipt of hepatitis A vaccine (VAQTA™)
19. Development of Pandemic Vaccines: ERVEBO Case Study
20. Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials
21. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
22. Immunology of gut mucosal vaccines
23. Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus – Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis
24. Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba
25. Clinical evaluation of adjuvants
26. Safety and Immunogenicity of CVD 1208S, a Live, Oral ΔguaBA Δsen Δset Shigella flexneri 2a Vaccine Grown on Animal-Free Media
27. A Clinical Study to Assess the Safety and Immunogenicity of Attenuated Measles Vaccine Administered Intranasally to Healthy Adults
28. Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
29. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial
30. Correction: A clinically parameterized mathematical model of Shigella immunity to inform vaccine design
31. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers
32. A clinically parameterized mathematical model of Shigella immunity to inform vaccine design
33. Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator
34. Antibody-Based Correlates of Protection against Cholera: Analysis of a Challenge Study of a Cholera-Naive Population
35. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae
36. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection WithVibrio choleraeO1 El Tor
37. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults.
38. Gut-Homing Conventional Plasmablasts and CD27− Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans
39. Erratum: Applications of nanotechnology for immunology
40. Shigella antigen-specific B memory cells are associated with decreased disease severity in subjects challenged with wild-type Shigella flexneri 2a
41. Applying Mathematical Tools to Accelerate Vaccine Development: Modeling Shigella Immune Dynamics
42. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers
43. Safety, tolerability, and immunogenicity of inactivated trivalent seasonal influenza vaccine administered with a needle-free disposable-syringe jet injector
44. Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine
45. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD− S. Typhi-specific IgA and IgG B memory cells in humans
46. Immunology of gut mucosal vaccines
47. Safety and Immunogenicity of CVD 1208S, a Live, OralΔguaBA Δsen Δset Shigella flexneri2a Vaccine Grown on Animal-Free Media
48. Intramedullary abscess of the spinal cord in children: a case report and review of the literature
49. Gut-homing conventional plasmablasts and CD27- plasmablasts elicited after a short time of exposure to an oral live-attenuated Shigella vaccine candidate in humans.
50. Gut-homing conventional plasmablasts and CD27- plasmablasts elicited after a short time exposure to an oral live attenuated Shigella vaccine candidate in humans.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.